Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include RNA modifications and cancer, Cancer-related molecular mechanisms research, Ferroptosis and cancer prognosis, and Bladder and Urothelial Cancer Treatments.
SRSF10 promotes cisplatin resistance in bladder cancer via BIN1 Exon 12 retention and ANXA1 activation.
Combined MEK and PARP inhibition enhances radiation response in rectal cancer
FAP promotes progression of oral leukoplakia via activation of PI3K/AKT pathway by interacting with ITGB1
Multi-omics reveals the impact of cancer-associated fibroblasts on the prognosis and treatment response of adult diffuse highest-grade gliomas
WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis.
Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
Hypoxia is correlated with the tumor immune microenvironment: Potential application of immunotherapy in bladder cancer.
Multi-Omics Clustering Reveals Disulfidptosis Typing in Hepatocellular Carcinoma and Correlates with Immune Features
UVB irradiation differential regulate miRNAs expression in skin photoaging
Se/Albumin Nanoparticles for Inhibition of Ferroptosis in Tubular Epithelial Cells during Acute Kidney Injury
Identification of novel subtypes based on ssGSEA in immune-related prognostic signature for tongue squamous cell carcinoma.
CD8<sup>+</sup> T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer.
Turning up the heat on non-immunoreactive tumors: pyroptosis influences the tumor immune microenvironment in bladder cancer.
MAFG-AS1/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis
Long noncoding RNA LINC00518 induces radioresistance by regulating glycolysis through an miR-33a-3p/HIF-1α negative feedback loop in melanoma.
Se@Albumin nanoparticles ameliorate intestinal mucositis caused by cisplatin<i>via</i>gut microbiota-targeted regulation
The long noncoding RNA <i>KTN1-AS1</i> promotes bladder cancer tumorigenesis via <i>KTN1 cis</i>-activation and the consequent initiation of Rho GTPase-mediated signaling
Analysis of tumor microenvironment characteristics in bladder cancer: implications for immune checkpoint inhibitor therapy
Identification and Validation of N6-methyladenosine-related Biomarkers for Bladder Cancer: Implications for Immunotherapy
The role of microenvironment in tumor angiogenesis
VDR activation attenuate cisplatin induced AKI by inhibiting ferroptosis.
SIRT1 Regulates N<sup>6</sup> -Methyladenosine RNA Modification in Hepatocarcinogenesis by Inducing RANBP2-Dependent FTO SUMOylation.
<i>MAFG‐AS1</i> promotes tumor progression via regulation of the HuR/PTBP1 axis in bladder urothelial carcinoma
LINC00467 is up-regulated by TDG-mediated acetylation in non-small cell lung cancer and promotes tumor progression.
MAFG-AS1 promotes tumor progression via regulation of the HuR/PTBP1 axis in bladder urothelial carcinoma.
Ubiquitin ligase CHAF1B induces cisplatin resistance in lung adenocarcinoma by promoting NCOR2 degradation.
The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo–TAZ pathway
Delivery of RIPK4 small interfering RNA for bladder cancer therapy using natural halloysite nanotubes.
The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway.
SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival